SciBrunch Therapeutics Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $35M

  • Investors
  • 6

SciBrunch Therapeutics General Information

Description

Operator of a biotechnology company focused on iterative innovation of small-molecule anti-tumor drugs. The company explores clinically validated targets from a new perspective, proactively designs differentiated product performance, and creates a globally competitive product pipeline.

Contact Information

Website
www.scibrunch.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Office Building, Kerry Centre, Pudong
  • Number 1155 Fangdian Road, Pudong New Area
  • Shanghai
  • China
+86 021
Primary Industry
Drug Discovery
Corporate Office
  • 4th Floor, Office Building, Kerry Centre, Pudong
  • Number 1155 Fangdian Road, Pudong New Area
  • Shanghai
  • China
+86 021

SciBrunch Therapeutics Timeline

20252026
Date FoundedFinancing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SciBrunch Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 30-Jan-2026 $35M Completed Generating Revenue
1. Seed Round 05-Jun-2025 Completed Startup
To view SciBrunch Therapeutics’s complete valuation and funding history, request access »

SciBrunch Therapeutics Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

SciBrunch Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026228575-A1 Compound of ras family Pending 28-Apr-2025
WO-2026223680-A1 Her2 inhibitor compound Pending 23-Apr-2025
WO-2026092561-A1 Macrocyclic compound Pending 30-Oct-2024
EP-4524142-A1 Fluoroquinoxalinone derivative for selectively inhibiting parp1 Pending 07-May-2022
EP-4524142-A4 Fluoroquinoxalinone derivative for selectively inhibiting parp1 Pending 07-May-2022 A61K31/4375
To view SciBrunch Therapeutics’s complete patent history, request access »

SciBrunch Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Highlight Capital Venture Capital Minority
InnoPinnacle Growth/Expansion Minority
BioTrack Capital Venture Capital Minority
Elikon Venture Growth/Expansion Minority
Hankang Capital Growth/Expansion Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

SciBrunch Therapeutics FAQs

  • When was SciBrunch Therapeutics founded?

    SciBrunch Therapeutics was founded in 2024.

  • Where is SciBrunch Therapeutics headquartered?

    SciBrunch Therapeutics is headquartered in Shanghai, China.

  • What industry is SciBrunch Therapeutics in?

    SciBrunch Therapeutics’s primary industry is Drug Discovery.

  • Is SciBrunch Therapeutics a private or public company?

    SciBrunch Therapeutics is a Private company.

  • What is SciBrunch Therapeutics’s current revenue?

    The current revenue for SciBrunch Therapeutics is .

  • How much funding has SciBrunch Therapeutics raised over time?

    SciBrunch Therapeutics has raised $62.7M.

  • Who are SciBrunch Therapeutics’s investors?

    Highlight Capital, InnoPinnacle, BioTrack Capital, Elikon Venture, and Hankang Capital are 5 of 6 investors who have invested in SciBrunch Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process